The 6 references in paper E. Anaev Kh., Э. Анаев Х. (2017) “Современные представления об идиопатическом легочном фиброзе: в фокусе – биомаркеры // Current concepts of idiopathic pulmonary fibrosis: focus on biomarkers” / spz:neicon:pulmonology:y:2017:i:1:p:56-64

1
Hutchinson J., Fogarty A., Hubbard R., McKeever T. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur. Respir. J. 2015; 46 (3): 795–806. DOI: 10.1183/09031936.00185114.
(check this in PDF content)
2
King T.E., Bradford W.Z., Castro-Bernardini S. et al. A phase 3 trial of pirfenidone in patients with idiopathic pulОбзоры monary fibrosis. N. Engl. J. Med.2014; 370 (22): 2083–2092. DOI: 10.1056/NEJMoa1402582.
(check this in PDF content)
3
Richeldi L., du Bois R.M., Raghu G. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med.2014; 370 (22): 2071–2082. DOI: 10.1056/ NEJMoa1402584.
(check this in PDF content)
4
Woodcock H.V., Maher T.M. The treatment of idiopathic pulmonary fibrosis. F1000Prime Rep.2014; 6: 16. DOI: 10.12703/P6-16.
(check this in PDF content)
5
Pathak R.R., DavéV. Integrating omics technologies to study pulmonary physiology and pathology at the systems level. Cell Physiol. Biochem. 2014; 33 (5): 1239–1260. DOI: 10.1159/000358693.
(check this in PDF content)
6
Raghu G., Collard H.R., Egan J.J. et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med.2011; 183 (6):
(check this in PDF content)